Improving the dismal outcomes reported following failure of a Bruton tyrosine kinase inhibitor (BTKi) represents a key challenge for providers caring for patients with mantle cell lymphoma (MCL; Jain et al., 2021; Martin et al., 2016; Rai et al., 2021). Partnering a BTKi alongside venetoclax (Venclexta), lenalidomide (Revlimid), bortezomib (Velcade), and/or an anti-CD20 monoclonal antibody, which have their own known activity in MCL, is a promising strategy (Davids et al., 2017, 2018; Eyre et al., 2018; Goy et al., 2009, 2013, 2015; Le Gouill et al., 2021; Tam et al., 2018, 2020; Trneny et al., 2016; Wang et al., 2012, 2016, 2021a; Witzig et al., 2017; Zinzani et al., 2013).
展开▼
